Total
0
Shares
G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva - The Market Herald
CEO, Dr Yacov Geva
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • G Medical Innovations (GMV) has expanded its agreement with HSC Technology to offer its remote patient monitoring services in Australia and New Zealand
  • This expansion allows hospitals and healthcare providers to remotely monitor their patients 24 hours a day
  • Patients who are enrolled in the service will be charged between $19 and $35 per month, which will be shared between G Medical, HSC Technology, and third-party providers
  • G Medical is up 6.60 per cent on the market and shares are currently trading for 5.7 cents each

G Medical Innovations (GMV) has expanded its agreement with HSC Technology to offer its remote patient monitoring services in Australia and New Zealand.

This extension follows a non-exclusive agreement secured in April where G Medical integrated and distributed its Prizma device via HSC's uVue telehealth platform to monitor the vital signs of elderly patients in a nursing home.

It also allows G Medical to introduce its 24-hour remote patient monitoring service to hospitals and other healthcare providers.

"The launch of a 24-hour remote patient monitoring service in Australia with a trusted and respected partner like HSC presents us with yet another avenue to grow our patient services infrastructure and recurring revenues," Director Dr Brendan de Kauwe said.

"HSC Technology Group will unlock an established network of healthcare providers and resellers, as well as a leading technology platform that G Medical can leverage quickly to drive uptake in Australia and New Zealand," he added.

Patients enrolled in the service will be charged between $19 and $35 per month, which will be shared between G Medical, HSC Technology, and third-party providers.

Additionally, this will allow G Medical to strengthen its footprint in Australia and New Zealand and unlock additional markets for its Prizma and Patch devices.

"Australia and New Zealand are important markets for G Medical and we believe we can establish a solid business here with the right partners," CEO and Managing Director Dr Yacov Geva commented.

G Medical is up 6.60 per cent on the market and shares are trading for 5.7 cents each at 1:30 pm AEST.

GMV by the numbers
More From The Market Herald
Jayex Healthcare (ASX:JHL) - Executive Chairman, Michael Boyd - The Market Herald

" Jayex Healthcare (ASX:JHL) to divest hospital queue management business

Jayex Healthcare (JHL) has entered into an asset sale to divest its on-premises hospital queue management business.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences’ (ASX:RHY) clinician network joins ColoSTAT trial

Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT.
Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

" Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

Shares in antiviral drug developer Island Pharmaceuticals (ILA) have jumped almost 150 per cent following the completion of a $7.5 million IPO.
Revasum (ASX:RVS) raises almost $7M via institutional entitlement offer

" Universal Biosensors (ASX:UBI) signs tech development deals

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.